NCT00538330Unknown不适用
Post Operative Adjuvant Chemotherapy Followed by Adjuvant Tamoxifen vs Nil for Patients With Operable Breast Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 入组人数
- 2,000
- 主要终点
- safety
研究概览
简要总结
Post operative adjuvant chemotherapy followed by adjuvant Tamoxifen vs nil for patients with operable breast cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with operable breast cancer
排除标准
- 未提供
结局指标
主要结局
safety
时间窗: 10 years
次要结局
未报告次要终点
研究者
相似试验
尚未招募
不适用
sefulness of postoperative adjuvant chemotherapy in patients with colorectal cancer T1/T2, N(+)colon cancerJPRN-UMIN000047044Japanese Foundation for Multidisciplinary Treatment of Cancer621
进行中（未招募）
1 期
Chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastasesThe CHARISMA randomized multicenter clinical trialEUCTR2013-004952-39-NLErasmus MC Cancer Institute224
已完成
3 期
eo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases ;The CHARISMA randomized multicenter clinical trialLiver metastases colorectal cancer1001981510017998NL-OMON44796Erasmus MC, Universitair Medisch Centrum Rotterdam224
尚未招募
不适用
Chemotherapy followed by versus surgery alone in high-risk patients with colorectal liver metastasesColorectal liver metastases, clinical risk score, high risk patients, colorectale levermetastasen, klinische risico score, hoog risico patientenNL-OMON27498Prof. Dr. C. VerhoefErasmus MC Cancer Institute224
招募中
2 期
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC PatientsImmunotherapyChemotherapyNCT05825443Nanfang Hospital, Southern Medical University57